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1 Research questions 
The EUnetHTA HTA Core Model® for Rapid Relative Effectiveness Assess-
ment of Pharmaceuticals was used for structuring this report [1]. The Model 
organises HTA information according to pre-defined generic research ques-
tions. Based on these generic questions, the following research questions were 
answered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is afatinib? 
A0022 Who manufactures afatinib? 
A0007 What is the target population in this assessment? 
A0020 For which indications has afatinib received marketing authorisation? 
Health problem and current use 
A0002 What is NSCLC? 
A0004 What is the natural course of NSCLC? 
A0006 What are the consequences of NSCLC for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of NSCLC? 
A0003 What are the known risk factors for NSCLC? 
A0024 How is NSCLC currently diagnosed according to published guidelines and in practice? 
A0025 How is NSCLC currently managed according to published guidelines and in practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of afatinib on mortality? 
D0006 How does afatinib affect the progression (or recurrence) of NSCLC? 
D0005 How does afatinib affect symptoms and findings (severity, frequency) of NSCLC? 
D0011 What is the effect of afatinib on patients’ body functions? 
D0012 What is the effect of afatinib on generic health-related quality of life? 
D0013 What is the effect of afatinib on disease-specific quality of life? 
Safety 
C0008 How safe is afatinib in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying afatinib? 
C0005 What are the susceptible patient groups that are more likely to be harmed  
through the use of afatinib? 
A0021 What is the reimbursement status of afatinib? 
 
 
 
 
EUnetHTA  
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Europe: Afatinib/Giotrif®; USA: Gilotrif®/L01XE13 
 
B0001: What is afatinib? 
Afatinib is a dual receptor tyrosine kinase (RTK) inhibitor [2]. It acts as a 
potent, selective and irreversible blocker of the ErbB family; this includes: 
epidermal-growth-factor-receptor (EGFR, ErbB1), HER2 (ErbB2), ErbB4 and 
specific EGFR mutations (e.g. alterations of L858R in exon 21 and deletions 
in exon 19) [3, 4]. The mechanism of action leads to the inhibition of tyrosine 
kinase auto phosphorylation, which in turn downregulates the ErbB signal-
ling. The downregulation of this signalling pathway results in the inhibition 
of tumour growth [5].  
The recommended dose of afatinib is 40 mg orally once daily. Treatment 
should be continued until disease progression or until no longer tolerated by 
the patient [3, 5].  
 
A0022: Who manufactures afatinib? 
Boehringer Ingelheim International GmbH 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Afatinib (Giotrif®) in combination with paclitaxel is indicated for the treat-
ment of erlotinib/gefitinib refractory/resistant non-small cell lung cancer 
(NSCLC) patients, who have progressed on afatinib monotherapy after ini-
tial benefit.  
 
 
 
4 Current regulatory status 
A0020: For which indications has afatinib received marketing authorisation? 
Afatinib (Giotrif®) monotherapy was approved by the European Medicines 
Agency (EMA) for the treatment of TKI-naive adult patients with locally ad-
vanced or metastatic NSCLC with activating EGFR mutations on 25 Sep-
tember 2013 [3]. In March 2016, the EMA approved afatinib for a new indi-
cation as follows: Afatinib (Giotrif®) monotherapy for the treatment of local-
ly advanced or metastatic NSCLC of squamous histology progressing on or 
after platinum-based chemotherapy [6]. 
dual RTK inhibitor 
once daily 40 mg orally  
for patients with NSCLC, 
refractory to erlotinib/ 
gefitinib & afatinib 
monotherapy 
approved by the EMA 
since 2013 
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The US Food and Drug Administration (FDA) approved afatinib (Gilotrif®) 
for the first-line treatment of NSCLC patients with EGFR exon 19 deletions 
or exon 21 (L858R) substitution mutations as detected by an FDA-approved 
test (therascreen® EGFR RGQ PCR Kit) on 12 July 2013. The use of afatinib 
is limited to these two EGFR mutations; safety and efficacy have not been 
ascertained in NSCLC patients exhibiting other EGFR mutations [5]. 
 
 
 
5 Burden of disease 
A0002: What is NSCLC? 
Lung cancer or bronchogenic carcinomas are malignancies that arise in the 
airways or pulmonary parenchyma [7]. They can be classified as either small-
cell lung cancer (SCLC) or NSCLC, which accounts for the majority of lung 
cancer patients (85%–90%) [8, 9]. There are three main types of NSCLC: 
squamous cell carcinoma, adenocarcinoma, and large-cell carcinoma [10]. 
 
A0004: What is the natural course of NSCLC? 
Generally, lung cancer is detected late in its natural history. A pulmonary 
nodule can grow and potentially metastasise before it causes any symptoms 
[11]. It can metastasise via the tissue, blood or lymph system [10]. Therefore, 
most patients with lung cancer have advanced disease at the time of diagno-
sis [11].  
Owing to the molecular pathogenesis of NSCLC, it is designated as a heter-
ogeneous group of disease [7]. The factor that has the greatest impact on 
prognosis of NSCLC is the tumour node metastasis (TNM) staging system. 
It classifies tumours on the basis of primary tumour characteristics (T), the 
presence or absence of regional lymph node involvement (N), and the pres-
ence or absence of distant metastases (M). The final stage (staged from I to 
IV) is dependent on the particular combination of T, N, and M characteris-
tics [12]. Of 100 newly diagnosed persons with lung cancer, 80 will be inop-
erable at presentation and about 20 will proceed to attempted resection [11]. 
 
A0006: What are the consequences of NSCLC for the society? 
A0023: How many people belong to the target population? 
About 12% of all malignant neoplasm cases in Austria are due to lung can-
cer. It is the most common cause of death as a result of cancer in males and 
second most common in females. In Austria, the incidence of lung cancer is 
30.5 per 100,000 persons per year; in 2012, more than 4,500 persons were new-
ly diagnosed, of whom one third already had remote metastasis [13]. Around 
17% of lung cancer patients are alive at least 5 years after diagnosis [14]. 
The median age at diagnosis of lung cancer is 70 years; it is more frequently 
diagnosed in males than in females (incidence 2012: 40.9 vs 22.0) [13, 15]. 
 
approved by the FDA 
since 2013 
definition of disease  
most patients have 
advanced diseases at 
initial presentation 
heterogeneous group  
of diseases 
incidence rate  
in Austria 30.5 per 
100,000 persons/year 
 
median age at diagnosis: 
70 years 
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A0005: What are the symptoms and the burden of NSCLC? 
Occasionally, lung cancer patients do not show any signs or symptoms [10]. 
Patients who are exhibiting symptoms are more likely to have chronic ob-
structive pulmonary diseases. In general, the most frequent symptoms of lung 
cancer imply cough, dyspnoea, weight loss, chest pain, haemoptysis, and short-
ness of breath [14, 16].  
 
A0003: What are the known risk factors for NSCLC? 
The predominant risk factor for developing lung cancer is cigarette smoking. 
It is estimated that smoking accounts for about 90% of all lung cancers [17]. 
The risk of a current smoker (one pack/day for 40 years) to develop lung can-
cer is around 20 times higher compared to someone who has never smoked 
[10]. Further, factors that may have an impact on the risk of lung cancer are: 
radiation therapy, environmental toxins (e.g. asbestos), pulmonary fibrosis, 
HIV infection, genetic factors, and alcohol [18]. 
 
A0024: How is NSCLC currently diagnosed  
according to published guidelines and in practice? 
A lung cancer screening is performed for high-risk current and former smok-
ers using low-dose computerised tomography (CT) scans. If highly suspicious 
nodules are detected by CT scans, biopsy or surgical excision should be per-
formed. For nodules with a low suspicion, further surveillance and the as-
sessment of other patient factors are recommended. Dependent on the size 
and location of the tumour, additional mediastinal or distant diseases, patient 
characteristics and local expertise, the diagnostic strategy should be person-
alised for each patient. Further, evaluation and staging are required if the bi-
opsy or surgical excision indicates a diagnosis of NSCLC [14, 19]. Patholog-
ic evaluation is needed to classify the histological type (e.g. determine the 
extent of invasion) of lung cancer. Following molecular diagnostics, studies 
should be performed to evaluate whether particular gene alterations are pre-
sent (i.e. EGFR mutations) [14, 20]. 
 
 
 
6 Current treatment 
A0025: How is NSCLC currently managed  
according to published guidelines and in practice? 
Certain factors have to be taken into account for the therapeutic decision: 
 Stage of cancer (TNM) 
 Type of NSCLC 
 Mutation in certain genes (e.g. EGFR, anaplastic lymphoma kinase 
(ALK) gene) 
 Health condition of the patient (Eastern Cooperative Oncology 
Group (ECOG) performance scale 0–4)[10] 
most common 
symptoms:  
cough, dyspnoea, 
weight loss, chest pain  
& shortness of breath  
main risk factor: 
cigarette smoking 
lung cancer screening 
via CT scans 
factors for  
therapeutic decisions 
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Stage I, II, or III NSCLC is commonly treated with curative intent using sur-
gery (provides the best chance of cure), chemotherapy, radiation therapy, or 
a combined modality approach [14, 21]. Systematic therapy is indicated for 
patients with stage IV (advanced disease) NSCLC or recurrence following in-
itial definitive treatment [21]. Therapy options for advanced NSCLC with-
out a driver mutation are: 
 initial treatment of NSCLC: four to six cycles of cytotoxic chemother-
apy with a platinum-based doublet (non-squamous tumour supplemen-
tation with bevacizumab). 
 therapy after combination chemotherapy: immunotherapy with an an-
ti-PD-1 antibody (e.g. nivolumab, pembrolizumab).  
 For patients who are not eligible for immunotherapy: single-agent 
chemotherapy with a non-cross-resistant agent is an alternative. 
Primary options for those who are receiving chemotherapy are 
pemetrexed (non-squamous tumours) and docetaxel [21, 22]. 
Therapy options for advanced NSCLC with a driver mutation are: 
 initial treatment of NSCLC: targeted inhibitor: e.g. erlotinib, gefitinib, 
or afatinib (EGFR), crizotinib (ALK fusion oncogene or ROS1 trans-
locations). 
 therapy after initial chemotherapy: targeted therapy with a specific 
inhibitor. 
 therapy after combination chemotherapy/treatment-specific inhibitor: 
single-agent chemotherapy as well as immunotherapy (e.g. nivolumab). 
 therapy after initial treatment with a targeted therapy: combination 
chemotherapy as in chemotherapy-naive patients [21, 22]. Another 
treatment option is osimertinib for patients with an activating muta-
tion of EGRF who have progressed after erlotinib, afatinib or geftinib 
[14]. 
 
 
 
7 Evidence 
A literature search was conducted on 18 April 2016 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were „Afatinib”, „Giotrif”, „Gilotrif”, „bibw-2992”, „non-small 
cell lung cancer” and „NSCLC”. Also, the manufacturer was contacted, who 
submitted three additional references (two of which had already been identi-
fied by systematic literature search). Manual search identified 25 additional 
references (web documents and journal articles). 
Overall, 425 references were identified. Included in this report are:  
 1 phase III study, assessing afatinib plus paclitaxel in NSCLC patients 
refractory to erlotinib, gefitinib, and afatinib monotherapy [23, 24]. 
 1 phase II study, assessing the clinical benefit of afatinib in patients 
with NSCLC who are resistant to erlotinib and/or gefitinib [25]. 
 
stage I, II, and III 
treatment with a 
curative intent 
no driver mutation: 
1st line: 4–6 cycles of 
cytotoxic chemotherapy 
2nd line immunotherapy 
or single-agent 
chemotherapy with  
a non-cross-resistant 
agent 
driver mutation: 
1st line:  
targeted inhibitor 
2nd line:  
targeted inhibitor 
single-agent 
chemotherapy & 
immunotherapy   
combination 
chemotherapy 
literature search in  
5 databases: 396 hits 
included: 
1 phase III study 
1 phase II study 
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7.1 Clinical efficacy and safety – 
phase III studies 
The LUX-Lung 5 trial (a randomised, multicentre, open-label international 
phase III study) was conducted to assess the efficacy and safety of afatinib 
plus paclitaxel (40 mg/day; 80 mg/m2/week) in patients with NSCLC, who 
had acquired resistance to erlotinib/gefitinib and had progressed on afatinib 
monotherapy after initial benefit [23, 24]. A total of 202 patients were random-
ly assigned in a 2:1 ratio to receive either afatinib plus paclitaxel (n = 134) 
or the investigator’s choice of a single-agent chemotherapy (n = 68).  
To assess the benefit of continued ErbB targeting beyond progression with 
afatinib, this trial consisted of a prior part (Part A), where patients were en-
rolled who had failed ≥ 1 line of chemotherapy and progressed following ≥ 12 
weeks’ clinical benefit on erlotinib/gefitinib. Every patient in Part A received 
single-agent afatinib (50 mg daily) to identify patients who derived clinical 
benefit from an ErbB blockade. However, participation in Part B was lower 
than expected as 351 patients (279 PFS events) would have been required to 
achieve 90% power at a two-sided 5% significance level for the log-rank test. 
In the end, only 202 patients were enrolled. As the calculated number of 351 
eligible patients was not achieved, the protocol was changed following dis-
cussion with the Safety Monitoring Committee (DMC) on 18 January 2013: 
the time point for the primary analyses of progression-free survival (PFS) and 
overall survival (OS) was adapted accordingly, and the analyses were carried 
out as soon as the final randomised patients could be followed up for at least 
6 months. Consequently, primary analysis was performed on 10 December 
2013, after 163 PFS events had occurred. 
Enrolled patients had a median age of 60 years. The study population had an 
Eastern Cooperative Oncology Group (ECOG) performance status of 0–2 and 
had received ≥ 1 line of chemotherapy (including platinum and pemetrex-
ed) and erlotinib/gefitinib after ≥ 12 weeks of treatment, and had to have 
obtained ≥ 12 weeks’ clinical benefit on afatinib monotherapy with subse-
quent progression pursuant to Response Evaluation Criteria in Solid Tumors 
(RECIST), version 1.1. Testing of the EGFR mutation status was not obliga-
tory. Detailed patient characteristics including inclusion and exclusion cri-
teria can be found in Table 3. 
The primary outcome of LUX-Lung 5 was PFS; secondary outcomes includ-
ed OS and objective response (OR). Other evaluated study endpoints were 
health-related quality of life (QoL, assessed with EQ-5D, QLQ-C30, and QLQ-
LC13) and safety. Adverse events were assessed in conformity with the Na-
tional Cancer Institute Common Terminology Criteria for Adverse Events 
(NCI-CTCAE), version 3.0.  
 
  
LUX-Lung 5:  
efficacy and safety  
of afa plus pac in  
202 patients 
required 351 patients  
for 90% power were  
not reached 
median age of 60 years 
and ECOG performance 
status of 0–2 
primary outcome: PFS 
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7.1.1 Clinical efficacy 
D0001: What is the expected beneficial effect of afatinib on mortality? 
The median OS was 12.2 (95% CI 10.2–14.9) months both in the afatinib-
paclitaxel group and in the chemotherapy group (12.2 months, 95% CI 9.33–
16.59). Compared with the control group, the hazard ratio (HR) of death was 
1.00 (95% CI 0.70–1.43, p = 0.994) in the afatinib-paclitaxel arm. There were 
no differences in OS among the two treatment groups. 
D0006: How does afatinib affect progression (or recurrence) of NSCLC? 
The primary endpoint, PFS, was significantly improved (p = 0.003) in the 
afatinib-paclitaxel group compared to the chemotherapy group. Median PFS 
was 5.6 (95% CI 5.1–6.3) months in the afatinib-paclitaxel group and 2.8 (95% 
CI 1.7–3.9) months in the chemotherapy group. The HR for disease progres-
sion for afatinib-paclitaxel compared to chemotherapy was 0.60 (95% CI 0.43–
0.85).  
 
D0005: How does afatinib affect symptoms and findings  
(severity, frequency) of NSCLC? 
The objective response rates (ORR) were 32.1% (afatinib-paclitaxel) and 13.2% 
(chemotherapy); a complete response (CR) was achieved by one patient in the 
afatinib-paclitaxel group. Stable disease (SD) rates were 42.5% in the afatinib-
paclitaxel group, and 32.4% in the chemotherapy group. The median dura-
tions of objective responses were 4.2 and 3.3 months in patients receiving 
afatinib-paclitaxel and in patients receiving chemotherapy respectively.  
 
D0011: What is the effect of afatinib on patients’ body functions? 
No evidence was found to answer this research question. 
 
D0012: What is the effect of afatinib on generic health-related quality of life? 
D0013: What is the effect of afatinib on disease-specific quality of life? 
There was a difference regarding median time to deterioration for dyspnoea 
(2.5 vs 1.6 months, p = 0.158) and pain (2.8 vs 1.7 months, p = 0.154) between 
the afatinib-paclitaxel group and the chemotherapy group. Patients receiving 
chemotherapy had a longer median time to deterioration for cough (6.5 vs 
5.4 months, p = 0.771) than patients who received afatinib-paclitaxel. Nev-
ertheless, none of the differences was statistically significant. Furthermore, 
the global health status did not differ between the two study groups.  
 
  
secondary endpoint: OS  
no difference between 
the two groups 
primary endpoint: PFS 
 
median PFS gain:  
2.8 months 
ORR 
afa+pac: 32.1% 
chemotherapy: 13.2% 
no statistically 
significant difference  
in QoL 
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Table 1: Efficacy results of the LUX-Lung 5 trial 
Descriptive statistics 
and estimate 
variability 
Treatment group Afatinib-paclitaxel Chemotherapy 
Number of subjects 134 68 
Median PFS, months 5.6 (5.1–6.3) 2.8 (1.7–3.9) 
Median OS, months 12.2 (10.2–14.9) 12.2 (9.33–16.59) 
ORR, % 
CR 
PR 
SD 
32.1 
0.7 
31.3 
42.5 
13.2 
0.0 
13.2 
32.4 
Median duration of 
objective response, 
months 
4.2 3.3 
Effect estimate  
per comparison 
 
Comparison groups 
Afatinib-paclitaxel 
vs chemotherapy 
PFS HR 0.60 
95% CI 0.43–0.85 
Log-rank test p value 0.003 
OS HR 1.00 
95% CI 0.70–1.43 
Log-rank test p value 0.994 
ORR OR 3.41 
95% CI 1.41–6.79 
Logistic regression p 
value 
0.005 
Abbreviations: CI = confidence interval, CR = complete response, HR = hazard ratio, OR = odds ratio, ORR = objective 
response rate, OS = overall survival, PFS = progression-free survival, PR = partial response, SD = stable disease 
 
7.1.2 Safety 
C0008: How safe is afatinib in relation to the comparator(s)? 
Adverse events (AEs) of any grade related to treatment were reported from 
88.6% (afatinib-paclitaxel) and 70% (chemotherapy) of patients. The most fre-
quent treatment-related AEs in the afatinib-paclitaxel group were diarrhoea 
(53.8%), alopecia (32.6%), asthenia (27.3%), decreased appetite (22.0%), and 
rash (20.5%).  
Treatment-related grade 3–5 AEs could be observed in 48.5% of patients re-
ceiving afatinib-paclitaxel and in 30.0% of patients receiving chemotherapy. 
In the afatinib-paclitaxel group serious treatment-related AEs were more com-
mon (11.4%) than in the chemotherapy group (3.3%). Treatment-related pe-
ripheral neuropathy occurred in 9.1% and 8.3% of patients in the afatinib-
paclitaxel group and in the chemotherapy group respectively. Treatment-
related fatal pneumonia was experienced by one patient, which was attribut-
ed to paclitaxel. Permanent discontinuation due to AEs occurred in 18.9% 
(afatinib-paclitaxel) and 6.7% (chemotherapy) of patients. All treatment-re-
lated AEs can be found in Table 2. 
 
any grade AEs 
afa+pac: 88.6% 
chemotherapy: 70% 
grade 3–5 AEs  
afa+pac: 48.5% 
chemotherapy: 30.0% 
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C0002: Are the harms related to dosage or frequency of applying afatinib? 
One or two dose reductions of afatinib were necessary in 27.3% and 4.5% of 
patients respectively. Regarding paclitaxel, 23.5% of patients required one 
dose reduction, and in 35.6% of patients the dosage was reduced a second 
time. In the chemotherapy group, the dose-reduction rate as a result of AEs 
was 11.7% compared to 32.6% in the afatinib-paclitaxel group. 
 
C0005: What are the susceptible patient groups  
that are more likely to be harmed through the use of afatinib? 
For pregnant women and patients who become pregnant while taking afatinib, 
there is a risk that it may cause foetal harm because of its mechanism of ac-
tion. Afatinib has not been studied yet in patients with severe hepatic and 
renal impairment [5].  
Table 2: Most frequent treatment-related adverse events1 
Adverse event  
(according to CTCAE, version 3.0) 
Afatinib-paclitaxel  
(n = 132) 
Chemotherapy  
(n = 60) 
 Any grade 
n (%) 
Grade 3–5 
n (%) 
Any grade 
n (%) 
Grade 3–5 
n (%) 
Any 117 (88.6) 64 (48.5) 42 (70.0) 18 (30.0) 
AEs leading to discontinuation 25 (18.9) 13 (9.8) 4 (6.7) 2 (3.3) 
Occurring in > 10% of patients in any study group 
Diarrhoea 71 (53.8) 16 (12.1) 4 (6.7) 0 (0) 
Alopecia 43 (32.6) 1 (0.8) 9 (15.0) 3 (5.0) 
Asthenia  36 (27.3) 11 (8.3) 17 (28.3) 2 (3.3) 
Decreased appetite 29 (22.0) 2 (1.5) 10 (16.7) 1 (1.7) 
Fatigue 27 (20.5) 6 (4.5) 9 (15.0) 3 (5.0) 
Rash 27 (20.5) 2 (1.5) 6 (10.0) 0 (0) 
Neutropenia 24 (18.2) 15 (11.3) 8 (13.3) 5 (8.3) 
Nausea 23 (17.4) 2 (1.5) 10 (16.7) 1 (1.7) 
Paronychia 23 (17.4) 3 (3.2) 0 (0) 0 (0) 
Vomiting 21 (15.9) 3 (2.3) 4 (6.7) 0 (0) 
Anaemia  20 (15.2) 5 (3.8) 3 (5.0) 0 (0) 
Leukopenia 20 (15.2) 6 (4.5) 7 (11.7) 3 (5.0) 
Epistaxis 16 (12.1) 0 (0) 1 (1.7) 0 (0) 
Stomatitis  13 (9.8) 2 (1.5) 2 (3.3) 0 (0) 
Mucosal inflammation 12 (9.1) 1 (0.8) 0 (0) 0 (0) 
Pruritus 10 (7.6) 0 (0) 3 (5.0) 1 (1.7) 
Dry skin 6 (4.5) 0 (0) 0 (0) 0 (0) 
Abbreviations: AEs = adverse events, CTCAE = Common Terminology Criteria for Adverse Events 
 
 
                                                             
1 Ordered by rate of occurrence in the afatinib-paclitaxel group 
higher dose-reduction 
rate in the intervention 
group 
embryo-foetal toxicity 
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7.2 Clinical efficacy and safety – 
further studies 
A multicentre, single-arm, open-label phase II trial [25] was conducted to as-
sess the clinical benefit of afatinib in patients with NSCLC who are resistant 
to erlotinib and/or gefitinib (≥ 12 weeks of prior treatment). Included were 
62 patients, 45 (72.6%) of whom had a positive EGFR mutation status in their 
primary tumour. The daily administered oral dose of afatinib was 50 mg. The 
primary endpoint was the objective response rate (ORR); secondary endpoints 
were overall survival (OS) and progression-free survival (PFS).  
ORR was 8.2%, of which five patients had a partial response (PR) and 35 
(57.4%) patients had a stable disease (SD) for ≥ 6 weeks. The median PFS 
was 4.4 months (95% CI 2.8–4.6) after 72.1% of patients had a PFS event. 
63.9% of patients had an OS event; median OS was 18.4 months. Most fre-
quent treatment-related adverse events (AEs) were rash (91.9%) and diarrhoea 
(100%). Discontinuation due to treatment-related AEs occurred in 29% of 
patients. Dose reductions to a daily 40-mg dose were necessary in 69.4% of 
patients.  
 
 
 
8 Estimated costs 
A0021: What is the reimbursement status of afatinib? 
In Austria, afatinib is available as 20, 30, 40, and 50-mg film-coated tablets in 
packages of 28 pieces each. One package of 28 40-mg tablets is available for 
€ 2,031.05 [26]. The recommended dose of afatinib is 40 mg orally once daily 
[5]. According to this dosage recommendation, the costs for a 30-day cycle 
would be € 2,176.13. Additional costs would incur due to the combination of 
afatinib with paclitaxel, which is administered at a dose of 80 mg/m² per week 
[23, 27]. Assuming a body surface of 1.70 m², total costs of about € 3,260 would 
incur for one month of combination therapy. 
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9 Ongoing research 
In May 2016, a search in databases www.clinicaltrials.gov and 
www.clinicaltrialsregister.eu was conducted. The following 6 ongoing  
phase III and IV trials are investigating afatinib in patients with NSCLC: 
 NCT02438722: A randomised phase II/III trial of afatinib plus cetux-
imab versus afatinib alone in treatment-naive patients with advanced, 
EGFR mutation-positive non-small cell lung cancer (NSCLC). Esti-
mated study completion date is February 2020.  
 NCT01953913: An open label, multicentre single-arm trial to assess 
the safety of afatinib for patients with locally advanced or metastatic 
non-small cell lung cancer (NSCLC) harbouring EGFR mutation(s). 
Estimated study completion date is July 2018. 
 NCT02695290: An open-label, single-arm phase IV study of afatinib 
in patients with stage IV or recurrent non-small cell lung cancer who 
have poor performance status and whose tumours have common epi-
dermal growth factor receptor (EGFR) mutations, exon 19 deletions or 
exon 21 (L858R) substitution mutations. Estimated study completion 
date is October 2018. 
 NCT02514174: A single-arm phase IV study of afatinib in elderly pa-
tients with stage IV or recurrent non-small cell lung cancer whose tu-
mours have epidermal growth factor receptor (EGFR) exon 19 dele-
tions or exon 21 (L858R) substitution mutations. Estimated study 
completion date is March 2018. 
 NCT01523587: LUX-Lung 8: A randomised, open-label phase III trial 
of afatinib versus erlotinib in patients with advanced squamous cell 
carcinoma of the lung as second-line therapy following first-line plat-
inum-based chemotherapy. Estimated study completion date is August 
2016. 
 NCT01121393: LUX-Lung 6: A randomised, open-label phase III study 
of BIBW 2992 versus chemotherapy as first-line treatment for patients 
with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR 
activating mutation. Estimated study completion date is December 
2016. 
Various phase I and II studies are currently ongoing in different treatment 
lines in patients with NSCLC, either using afatinib monotherapy or combi-
nation treatment (e.g. NCT02364609, NCT01999985, NCT01542437, and 
NCT02625168). In addition, afatinib is also currently investigated for other 
indications, like squamous cell carcinoma of the head and neck, brain can-
cer, advanced oesophago-gastric cancer, and advanced refractory urothelial 
cancer.  
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10 Discussion 
At the moment, afatinib in combination with paclitaxel for the treatment of 
erlotinib/gefitinib-refractory NSCLC patients who have progressed on afat-
inib after initial benefit is neither by the EMA nor by the FDA. However, 
afatinib received marketing authorisation in the US (July 2013) as well as in 
Europe (September 2013) for the treatment of EGFR TKI-naive adult patients 
with locally advanced or metastatic NSCLC with activating EGFR mutations. 
Recently (March 2016), afatinib monotherapy was also approved by the EMA 
for the treatment of locally advanced or metastatic NSCLC of squamous his-
tology progressing on or after platinum-based chemotherapy [3, 5]. 
A randomised, open-label phase III study, the LUX-Lung 5 trial [23], com-
pared afatinib in combination with paclitaxel with single-agent chemotherapy 
in patients with NSCLC refractory/resistant to erlotinib/gefitinib after initial 
benefit of afatinib monotherapy in 202 patients. For patients treated with afat-
inib-paclitaxel, median PFS was significantly longer compared to the chemo-
therapy group (5.6 vs 2.8 months). Median OS did not differ between the two 
tested groups (p = 0.994). ORR was 32.1% in the afatinib-paclitaxel group 
versus 13.2% in the chemotherapy group. 
In terms of safety, treatment-related AEs of any grade as well as of grade 3–5 
were more common in the afatinib-paclitaxel group compared to the chemo-
therapy group. The most frequent AEs in the afatinib-paclitaxel arm were di-
arrhoea, alopecia, asthenia, decreased appetite, and rash. The discontinuation 
rate was higher in the afatinib-paclitaxel group compared to the chemothera-
py group (18.9% vs 8.3%). No significant differences regarding QoL could be 
identified between the two study arms.  
The stratification of randomisation was based on the duration of benefit on 
previous gefitinib/afatinib treatment and sex. However, there is an imbalance 
in the number of post-progression therapies as well as in the EGFR status. 
Additionally, more patients in the intervention group had a better health sta-
tus (ECOG 0: 35.1% vs 20.6%) as well as less lines of previous treatment (0 or 
1 line: 34.3% vs 20.5%). The study was conducted in two parts: A and B. In 
Part B, which followed Part A, 202 patients with ≥ 12 weeks’ clinical benefit 
on afatinib monotherapy with subsequent progression (according to RECIST) 
were eligible for the experimental part of the study. As only 14 patients in 
Part B had a confirmed EGFR mutation status (9 positive, 5 negative), it is 
not known whether the EGFR mutation status among the remaining 190 pa-
tients was balanced between the two arms. 
Documentation of the enrolled patients’ EGFR mutation status was not ob-
ligatory. However, afatinib is currently approved in Europe as well as in the 
US for the first-line treatment of NSCLC patients with activating EGFR mu-
tation. Therefore, prior testing via re-biopsy or liquid biopsy would be im-
portant to detect patients who are exhibiting an activating EGFR mutation. 
This could help to identify any advantages or disadvantages for patients with 
a positive/negative EGFR status receiving afatinib and paclitaxel as a late-line 
treatment. 
A statistical limitation of the study is that 351 patients would have been nec-
essary for the primary analysis to achieve 90% power at a two-sided 5% sig-
nificance level for the log rank tests. As this patient number was not achieved, 
the time point for the primary analysis was changed, and only 202 patients 
not approved by the 
EMA or the FDA 
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(57.5% of the required patient number) were enrolled in the study. This nega-
tively influences the probability that a nominally statistically significant find-
ing actually represents a true effect. Further, problems that occurred were an 
exaggerated estimate of the magnitude of the effect, and possibly increased 
the bias [28]. 
Another issue is that, due to the small sample size of various subgroups, it is 
not possible to make a clear statement about consistent PFS benefit across 
predefined subgroups. For instance, there is a trend of favouring chemother-
apy in patients who have a smoking history of < 15 pack years and stopped 
> 1 year. Therefore, it would be important to investigate the PFS benefit of 
afatinib-paclitaxel in a higher patient number for different subgroups, in 
which uncommon and common mutations are also taken into account. 
Generally, the median age at diagnosis of lung cancer is 70 years; further, 
lung cancer is commonly detected late in its natural history. Since patients 
were on average about 60 years old and had an ECOG score between 0 and 1 
in 91% of cases, the study population conceivably did not reflect the patient 
group most affected by NSCLC in clinical practice. 
Furthermore, response assessment by a local investigator increases the po-
tential of bias and measurement errors. If there are differences in evaluation 
times correspondent to treatment arms, evaluation-time bias can occur [29]. 
In addition, as the primary endpoint of the study was PFS, an attrition bias 
may be possible since it is difficult to determine a patient’s progression time 
as soon as they are lost to follow-up [30]. 
However, another treatment option for the late-line therapy of NSCLC is the 
combination of afatinib with another inhibitor. For instance, the combina-
tion of afatinib with PI3K/Akt/mTOR inhibitors or SRC kinase inhibitors 
may be of interest in order to increase the efficacy of and protract resistance 
to monotherapies. The limitation of these combination therapies is often re-
duced tolerability because of dose-limiting toxicity [8, 31]. Therefore, anoth-
er option, in particular for EGFRT790M-positive patients, is a treatment with 
third-generation EGFR inhibitors (e.g. CO-1686, AP26113) [8].  
The costs per month for the treatment with afatinib-paclitaxel amount to 
€ 3,260. Additional costs could incur due to obligatory testing of the EGFR 
mutation status if further trials were to identify a benefit for EGFR-positive 
patients.  
In conclusion, the treatment with afatinib-paclitaxel offers modest improve-
ments in PFS (median gain 2.8 months) and no gain in OS at relatively high 
costs per month (€ 3,260) and a greater extent of AEs. Therefore, other afat-
inib-based combination therapies as well as third-generation inhibitors might 
be taken into consideration for the late-line treatment of NSCLC patients 
refractory to erlotinib/gefitinib and afatinib monotherapy. In addition, fur-
ther trials are needed to evaluate the efficacy and safety for different sub-
groups who exhibit common/uncommon mutations, especially regarding the 
EGFR mutation status. Finally, the fact that the study was underpowered 
due to the small sample size (42.5% fewer patients than necessary) also has 
to be taken into account when considering the efficacy and safety results. 
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12 Appendix 
Table 3: Characteristics of the LUX-Lung 5 trial 
Title: Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, 
erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial [23, 24] 
Study identifier NCT01085136, EudraCT number 2009-014563-39, LUX-Lung 5 
Design Phase III, randomised, multicentre, open-label, international trial 
Duration Enrolment: April 2010 to May 2011 
The study was conducted in two parts (A and B). In Part A, 
1,154 patients were enrolled who had failed ≥ 1 line of 
chemotherapy and who had progressed ≥ 12 weeks after 
clinical benefit on erlotinib/gefitinib. Upon progression, 
patients with ≥ 12 weeks on afatinib were eligible for Part B. 
As the required patient number for Part B was not reached, 
the protocol was changed following discussion with the 
Safety Monitoring Committee on 18 January 2013. The time 
point for the primary analyses of PFS and OS was amended 
accordingly, and the analyses were carried out as soon as 
the final randomised patients could be followed up for at 
least 6 months. Consequently, primary analysis was 
performed on 10 December 2013. 
Hypothesis Superiority 
The study was designed to show a prolonged PFS (HR 0.67) in patients treated with afatinib 
plus paclitaxel compared to those who received the investigator’s choice of single-agent 
chemotherapy. The planned sample size of the study was 351 patients to provide 90% power  
at a two-sided 5% significance level for the log-rank test. The required patient number was  
not reached (n = 202). 
Funding Boehringer Ingelheim International GmbH 
Treatments  
groups 
Intervention (n = 134) 
Afatinib 40 mg/day, with dose reductions to 30 mg/day 
and 20 mg/day – oral 
Paclitaxel 80 mg/m² once weekly (7 weeks on/1 week off;  
2 dose reductions were allowed) – intravenous 
Control (n = 68) 
Investigator’s choice of chemotherapy dosage was 
dependent on schedule (2 dose reductions were allowed) – 
intravenous/oral 
Endpoints and 
definitions 
Progression-free survival 
(primary outcome) 
PFS Day of randomisation to the day of progression according 
to RECIST, version 1.1 
Overall survival OS Time from the date of randomisation to the date of death 
Objective response rate ORR Best overall response of complete response or partial 
response as determined by RECIST 1.1 and as assessed  
by the investigator 
Results and analysis  
Analysis 
description 
Primary analysis 
Efficacy analyses were performed in the randomised set (all randomised patients irrespective 
of whether they were treated or not); no information on the included study population is 
available regarding safety and QoL analysis. PFS and OS were analysed by a stratified log-rank 
test. For HRs and CIs a stratified Cox proportional hazards model was used. A logistic regression 
was used to identify differences in the objective response rates (ORR; CR + PR). 
Analysis 
population  
Inclusion  Stage IIIB (wet) or IV NCSLC with measurable disease 
 Failure of treatment with ≥ 1 line of chemotherapy  
(including platinum and pemetrexed)  
  Erlotinib/gefitinib after ≥ 12 weeks of treatment  
 ≥ 12 weeks’ clinical benefit on afatinib monotherapy with subsequent 
progression according to RECIST, version 1.1 
 Age ≥ 18 years 
 ECOG performance status of 0–2 
 Life expectancy of ≥ 12 weeks  
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Title: Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, 
erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial [23, 24] 
Study identifier NCT01085136, EudraCT number 2009-014563-39, LUX-Lung 5 
Analysis  
population  
(continuation) 
Exclusion  Absence of clinical benefit from afatinib monotherapy 
 Abnormal hepatic, renal or hematologic function 
 Pregnancy and breastfeeding 
 Peripheral polyneuropathy of > grade 2 
 Pre-existing or current interstitial lung disease 
 Other malignancies diagnosed within the past five years  
(other than non-melanomatous skin cancer and in-situ cervical cancer) 
 Clinically relevant cardiovascular abnormalities (uncontrolled hypertension, 
congestive heart failure – New York Heart Association functional 
classification of III, unstable angina, or poorly controlled arrhythmia)  
 Myocardial infarction within 6 months prior to entering the trial 
 Absolute neutrophil count at or less than 1,500/mm³ 
 Platelet count at or less than 100,000/mm³ 
 Bilirubin at or greater than 1.5 mg/dL (> 26 mol/L, SI unit equivalent) 
 Patients with any serious active infection including known human 
immunodeficiency virus (HIV), active hepatitis B or active hepatitis C 
 Known or suspected active drug or alcohol abuse 
 Significant or recent acute gastrointestinal disorders (diarrhoea  major 
symptoms, e.g. Crohn’s disease, mal-absorption, or CTCAE grade > 2 diarrhoea 
of any aetiology at baseline) 
Characteristics afatinib-paclitaxel chemotherapy2 
Median age, years 60.0 60.5 
Gender: n (%) ♂ 69 (51.5) 
♀65 (48.5) 
♂ 34 (50.0) 
♀ 34 (50.0) 
Baseline ECOG status, n (%) 
0 
1 
2 
 
47 (35.1) 
77 (57.5) 
10 (7.5) 
 
14 (20.6) 
46 (67.6) 
8 (11.8) 
Smoking status, n (%) 
Never smoked 
< 15 pack years, stopped > 1 year before diagnosis 
Current/other ex-smoker 
 
71 (53.0) 
14 (10.4) 
49 (36.6) 
 
37 (54.4) 
10 (14.7) 
21 (30.9) 
Tumour histology, n (%) 
Adenocarcinoma 
Squamous 
Other  
 
113 (84.3) 
11 (8.2) 
10 (7.5) 
 
61 (89.7) 
6 (8.8) 
1 (1.5) 
Confirmed EGFR mutation status, n (%) 
Positive 
Negative 
 
6 (4.5) 
2 (1.5) 
 
3 (4.4) 
3 (4.4) 
Prior EGFR TKI therapy, n (%) 
Erlotinib 
Gefitinib 
Both 
 
96 (71.6) 
32 (23.9) 
6 (4.5) 
 
47 (69.1) 
16 (23.5) 
5 (7.4) 
Lines of prior chemotherapy, n (%) 
0 
1 
2 
> 2 
 
5 (3.7) 
41 (30.6) 
39 (29.1) 
49 (36.6) 
 
2 (2.9) 
12 (17.6) 
28 (41.2) 
26 (38.2) 
                                                             
2 Paclitaxel (35.0%), docetaxel (15.0%), pemetrexed (26.7%), vinorelbine (8.3%), gemcitabine (6.7%),  
carboplatin (1.7%), and non-protocol defined chemotherapy (6.7%) 
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Title: Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, 
erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial [23, 24] 
Study identifier NCT01085136, EudraCT number 2009-014563-39, LUX-Lung 5 
Analysis  
population  
(continuation) 
Previous pemetrexed  
Yes  
No 
 
72 (53.7) 
62 (46.3) 
 
39 (57.4) 
29 (42.6) 
Previous taxane, n (%) 
Yes 
No 
 
67 (50.0) 
67 (50.0) 
 
38 (55.9) 
30 (44.1) 
Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events, ECOG = Eastern Cooperative Oncology Group, 
EGFR = Epidermal Growth Factor Receptor, NSCLC = non-small cell lung cancer, RECIST = Response Evaluation Criteria 
in Solid Tumors, TKI = tyrosine kinase inhibitor 
 
Table 4: Risk of bias assessment on study level is based on EUnetHTA  
(Internal validity of randomized controlled trials) [32] 
Criteria for judging risk of bias risk of bias 
Adequate generation of randomisation sequence unclear 
Adequate allocation concealment unclear 
Blinding 
Patient no 
Treating Physician no 
Selective outcome reporting unlikely no 
No other aspects which increase the risk of bias no 
Risk of bias – study level high 
 
 
 
 
